Fly News Breaks for February 25, 2020
Feb 25, 2020 | 08:04 EDT
Raymond James analyst Jayson Bedford raised his price target for Tandem Diabetes to $91 from $85, saying that while Q4 results were in-line with consensus, 2020 guidance was roughly 3% ahead of consensus, with upside coming from better U.S. growth. Bedford tells investors in a research note that he continues to believe Tandem has the best therapy for people with type 1 diabetes, and with U.S. pump penetration at less than 20% of insulin users, believes the opportunity for market growth and share gains is large.
News For TNDM From the Last 2 Days